Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

被引：0

作者：

Roch Houot

Guillaume Cartron

Fontanet Bijou

Sophie de Guibert

Gilles A. Salles

Christophe Fruchart

Krimo Bouabdallah

Marie Maerevoet

Pierre Feugier

Steven Le Gouill

Hervé Tilly

Rene-Olivier Casasnovas

Cécile Moluçon-Chabrot

Eric Van Den Neste

Pierre Zachee

Marc Andre

Christophe Bonnet

Corinne Haioun

Achiel Van Hoof

Koen Van Eygen

Lysiane Molina

Emmanuelle Nicolas-Virelizier

Philippe Ruminy

Franck Morschhauser

机构：

[1] University Hospital of Rennes,Department of Clinical Hematology

[2] Inserm 0203,Department of Clinical Hematology

[3] University of Rennes,Department of Hematology

[4] University Hospital of Montpellier,undefined

[5] UMR CNRS 5235,undefined

[6] University of Montpellier,undefined

[7] French Blood Institute,undefined

[8] Department of Hematology,undefined

[9] Centre Hospitalier Lyon-Sud,undefined

[10] Institut d’Hématologie de Basse Normandie (IHBN),undefined

[11] CHU,undefined

[12] Haematology,undefined

[13] CHU de Bordeaux,undefined

[14] Hematology,undefined

[15] Institut Jules Bordet,undefined

[16] CHU et INSERM 954,undefined

[17] Nancy Université,undefined

[18] Nantes University Hospital and UMR892 INSERM,undefined

[19] Centre Henri Becquerel,undefined

[20] Inserm U918,undefined

[21] Université de Rouen,undefined

[22] IRIB,undefined

[23] Hematology,undefined

[24] University Hospital,undefined

[25] Hematology Department,undefined

[26] CHU Clermont Ferrand,undefined

[27] Department of Hematology,undefined

[28] Cliniques Universitaires Saint-Luc,undefined

[29] AZ GROENINGE,undefined

[30] Hematology Department,undefined

[31] CHU UCL NAMUR,undefined

[32] Clinical Hematology,undefined

[33] CHU University of Liège,undefined

[34] Hôpital Henri Mondor,undefined

[35] Unité Hémopathies Lymphoide,undefined

[36] General Hospital St-Jan,undefined

[37] ZNA Stuivenberg,undefined

[38] Hematology,undefined

[39] CHU de Grenoble,undefined

[40] Hematology Department,undefined

[41] Centre Léon Bérard,undefined

[42] Université de Lille/ hopital Claude Huriez,undefined

来源：

Leukemia | 2019年 / 33卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：776 / 780

页数：4

共 50 条

[1] Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study
Houot, Roch
Cartron, Guillaume
Bijou, Fontanet
de Guibert, Sophie
Salles, Gilles A.
Fruchart, Christophe
Bouabdallah, Krimo
Maerevoet, Marie
Feugier, Pierre
Le Gouill, Steven
Tilly, Herve
Casasnovas, Rene-Olivier
Molucon-Chabrot, Cecile
Van den Neste, Eric
Zachee, Pierre
Andre, Marc
Bonnet, Christophe
Haioun, Corinne
Van Hoof, Achiel
Van Eygen, Koen
Molina, Lysiane
Nicolas-Virelizier, Emmanuelle
Ruminy, Philippe
Morschhauser, Franck
LEUKEMIA, 2019, 33 (03) : 776 - 780
[2] A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma
Morschhauser, Franck
Cartron, Guillaume
Salles, Gilles A.
Bijou, Fontanet
Fruchart, Christophe
Bouabdallah, Krimo
Feugier, Pierre
Le Gouill, Steven
Tilly, Herve
Molucon-Chabrot, Cecile
Maerevoet, Marie
Casasnovas, Rene-Olivier
Van den Neste, Eric W.
Zachee, Pierre
Van Eygen, Koen
Van Hoof, Achiel
Bonnet, Christophe
Haioun, Corinne
Andre, Marc
Xerri, Luc
Houot, Roch
BLOOD, 2016, 128 (22)
[3] A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma
Fowler, Nathan H.
Nastoupil, Loretta J.
Chin, Collin
Strati, Paolo
Hagemeister, Fredrick B.
Fayad, Luis E.
Westin, Jason R.
Forbes, Sheryl G.
Arafat, Janine
Feng, Lei
Nair, Ranjit
Steiner, Raphael E.
Samaniego, Felipe
Neelapu, Sattva S.
BLOOD, 2019, 134
[4] Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study
Bachy, Emmanuel
Houot, Roch
Feugier, Pierre
Bouabdallah, Krimo
Bouabdallah, Reda
Virelizier, Emmanuelle Nicolas
Maerevoet, Marie
Fruchart, Christophe
Snauwaert, Sylvia
Le Gouill, Steven
Marolleau, Jean-Pierre
Molina, Lysiane
Molucon-Chabrot, Cecile
Thieblemont, Catherine
Tilly, Herve
Bijou, Fontanet
Haioun, Corinne
Van den Neste, Eric
Fabiani, Bettina
Meignan, Michel
Cartron, Guillaume
Salles, Gilles
Casasnovas, Olivier
Morschhauser, Franck
BLOOD, 2022, 139 (15) : 2338 - 2346
[5] A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy
Morschhauser, Franck
Salles, Gilles Andre
Casasnovas, Rene-Olivier
Feugier, Pierre
Bouabdallah, Krimo
Cartron, Guillaume
Bouabdallah, Reda
Nicolas-Virelizier, Emmanuelle
Maerevoet, Marie
Snauwaert, Sylvia
Fruchart, Christophe
Gouill, Steven L. E.
Molucon-Chabrot, Cecile
Delette, Caroline
Molina, Lysiane
Tilly, Herve
Thieblemont, Catherine
Van Den Neste, Eric
Bijou, Fontanet
Fabiani, Bettina
Haioun, Corinne
Houot, Roch
BLOOD, 2018, 132
[6] Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Morschhauser, Franck
Le Gouill, Steven
Feugier, Pierre
Bailly, Sarah
Nicolas-Virelizier, Emmanuelle
Bijou, Fontanet
Salles, Gilles A.
Tilly, Herve
Fruchart, Christophe
Van Eygen, Koen
Snauwaert, Sylvia
Bonnet, Christophe
Haioun, Corinne
Thieblemont, Catherine
Bouabdallah, Reda
Wu, Ka Lung
Canioni, Danielle
Meignin, Veronique
Cartron, Guillaume
Houot, Roch
LANCET HAEMATOLOGY, 2019, 6 (08): : E429 - E437
[7] ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Zinzani, Pier Luigi
Mayer, Jiri
Flowers, Christopher R.
Bijou, Fontanet
De Oliveira, Ana C.
Song, Yuqin
Zhang, Qingyuan
Merli, Michele
Bouabdallah, Krimo
Ganly, Peter
Zhang, Huilai
Johnson, Roderick
Martin Garcia-Sancho, Alejandro
Provencio Pulla, Mariano
Trneny, Marek
Yuen, Sam
Tilly, Herve
Kingsley, Edwin
Tumyan, Gayane
Assouline, Sarit E.
Auer, Rebecca
Ivanova, Elena
Kim, Pil
Huang, Sha
Delarue, Richard
Trotman, Judith
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (33) : 5107 - +
[8] Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study.
Fowler, Nathan Hale
Neelapu, Sattva Swarup
Samaniego, Felipe
Forbes, Sheryl
Hagemeister, Fredrick B.
Fayad, Luis
Feng, Lei
Turturro, Francesco
Westin, Jason R.
Arafat, Janine
Neal, Eleanor
Nastoupil, Loretta J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
Morschhauser, Franck
Ghosh, Nilanjan
Lossos, Izidore S.
Palomba, M. Lia
Mehta, Amitkumar
Casasnovas, Olivier
Stevens, Don
Katakam, Sudhakar
Knapp, Andrea
Nielsen, Tina
McCord, Ron
Salles, Gilles
BLOOD CANCER JOURNAL, 2021, 11 (08)
[10] Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
Franck Morschhauser
Nilanjan Ghosh
Izidore S. Lossos
M. Lia Palomba
Amitkumar Mehta
Olivier Casasnovas
Don Stevens
Sudhakar Katakam
Andrea Knapp
Tina Nielsen
Ron McCord
Gilles Salles
Blood Cancer Journal, 11

← 1 2 3 4 5 →